The US Food and Drug Administration (FDA) has approved ofatumumab injection (Kesimpta, Novartis) for the treatment of adults with relapsing forms of multiple sclerosis, including relapsing-remitting ...

A new injection drug can prevent multiple sclerosis flare-ups better than an existing medication, a clinical trial has found. The drug, called ofatumumab, beat a standard MS medication in reducing ...

The digital press release with multimedia content can be accessed here: Basel, August 20, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® ...

Kesimpta, a CD20-directed cytolytic monoclonal antibody, is the first B-cell therapy intended for patient self-administration. The Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab ...

The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.

Kesimpta® (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adults First B-cell therapy that can be self-administered using Sensoready® autoinjector pen ...

Patients with relapsing forms of multiple sclerosis have a new treatment that can be self-administered at home. The Food and Drug Administration has approved Novartis’ Kesimpta (ofatumumab, formerly ...

STOCKHOLM -- Ofatumumab, a B-cell targeting monoclonal antibody being evaluated for relapsing forms of multiple sclerosis (MS), outperformed teriflunomide (Aubagio) in reducing annualized relapse rate ...

Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully ...

For multiple sclerosis, the therapy will be sold as Kesimpta by Novartis; it is administered by patients once a month through the Sensoready autoinjector pen. The FDA on Thursday approved a new ...

The US Food and Drug Administration (FDA) has granted full approval to ofatumumab (Arzerra Injection, for intravenous infusion; GlaxoSmithKline) for chronic lymphocytic leukemia (CLL). The indication ...

Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which ...